Featured Publications
The Vascular Quality Initiative assessment of the Bard Lifestent for the treatment of popliteal artery occlusive disease
Bertges D, Eldrup-Jorgensen J, Eskandari M, Hamdan A, Mena-Hurtado C, Mewissen M, Smith T, Woo E, Cronenwett J, Initiative S. The Vascular Quality Initiative assessment of the Bard Lifestent for the treatment of popliteal artery occlusive disease. Journal Of Vascular Surgery 2023, 78: 1489-1496.e1. PMID: 37648091, DOI: 10.1016/j.jvs.2023.08.122.Peer-Reviewed Original ResearchConceptsTarget lesion revascularizationChronic limb-threatening ischemiaTarget vessel revascularizationMajor adverse eventsLimb-threatening ischemiaPopliteal arteryLesion revascularizationMajor amputationVessel revascularizationHemodynamic successSecondary patencyAdverse eventsOcclusive diseaseProcedural successSingle-arm prospective studyProximal popliteal arterySustained clinical successPrimary efficacy outcomePrimary safety outcomeArtery occlusive diseaseComposite primary endpointPrimary-assisted patencyKaplan-Meier analysisSuperficial femoral arteryMajority of stents
2020
Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis
Weissler EH, Annapureddy A, Wang Y, Secemsky EA, Shishehbor MH, Mena-Hurtado C, Jelani QU, Aronow HD, Tsai TT, Patel MR, Curtis JP, Jones WS. Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis. American Heart Journal 2020, 233: 59-67. PMID: 33321119, PMCID: PMC8078180, DOI: 10.1016/j.ahj.2020.12.004.Peer-Reviewed Original ResearchConceptsPeripheral vascular interventionsPCD usePaclitaxel-coated devicesChronic total occlusionSignificant differencesCause mortalityAnalytic cohortFemoropopliteal lesionsOverall cohortPopliteal arteryPrimary outcomeRegistry analysisTotal occlusionUnadjusted ratesFemoropopliteal stenosesInverse probability weightingVascular interventionsAmerican CollegePatientsPractice settingsMortalityReal-world useClaim outcomesDevice useOutcomes
2019
Drug‐coated balloon versus plain old balloon angioplasty in femoropopliteal disease: An updated meta‐analysis of randomized controlled trials
Anantha‐Narayanan M, Shah SM, Jelani Q, Garcia S, Ionescu C, Regan C, Mena‐Hurtado C. Drug‐coated balloon versus plain old balloon angioplasty in femoropopliteal disease: An updated meta‐analysis of randomized controlled trials. Catheterization And Cardiovascular Interventions 2019, 94: 139-148. PMID: 30838719, DOI: 10.1002/ccd.28176.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmputation, SurgicalAngioplasty, BalloonCardiovascular AgentsCoated Materials, BiocompatibleEquipment DesignFemaleFemoral ArteryHumansLimb SalvageMalePeripheral Arterial DiseasePopliteal ArteryRandomized Controlled Trials as TopicRisk FactorsTreatment OutcomeVascular Access DevicesVascular PatencyConceptsTarget vessel revascularizationPeripheral arterial diseaseFemoropopliteal diseaseBalloon angioplastyRate of TVRDrug-coated balloon angioplastyPlain old balloon angioplastyAvailable RCT dataDevice-related mortalityImproved vessel patencyPrimary safety endpointMainstay of therapyCochrane's Q statisticLate lumen lossDrug-coated balloonsRandom-effects modelQ statisticMajor amputationSafety endpointVessel revascularizationDCB groupPopliteal arteryArterial diseaseUse of DCBLumen loss